Juan Maza-Solano, Vicente Merino-Bohórquez, Ana Gómez-Bastero, Julio Delgado-Romero, Serafín Sánchez-Gomez
{"title":"Real-life outcomes of benralizumab treatment in chronic rhinosinusitis with nasal polyps: The BenREALizumab Study.","authors":"Juan Maza-Solano, Vicente Merino-Bohórquez, Ana Gómez-Bastero, Julio Delgado-Romero, Serafín Sánchez-Gomez","doi":"10.1016/j.otoeng.2025.512291","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a significant impact on quality of life. Benralizumab has shown efficacy in severe eosinophilic asthma, but there is limited evidence for CRSwNP. A prospective observational study was conducted in a tertiary hospital with six adults with severe CRSwNP, according to EPOS2020 criteria, treated for 52 weeks. All had multiple surgeries (mean 3.3) and high cumulative exposure to systemic corticosteroids. Initially, they presented a high symptom and endoscopic burden (SNOT-22: 72; NPS: 5.2). After 16 and 52 weeks, significant improvements were observed in SNOT-22 (40.3 and 28.8), NPS (4.3 and 2.7), corticosteroid use, and complete eosinophil depletion. VAS scores improved, especially in smell, rhinorrhea, and general condition. No significant adverse events occurred. These preliminary results suggest that benralizumab may be effective in CRSwNP without associated asthma, although larger controlled studies are needed.</p>","PeriodicalId":93855,"journal":{"name":"Acta otorrinolaringologica espanola","volume":" ","pages":"512291"},"PeriodicalIF":0.0000,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta otorrinolaringologica espanola","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.otoeng.2025.512291","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a significant impact on quality of life. Benralizumab has shown efficacy in severe eosinophilic asthma, but there is limited evidence for CRSwNP. A prospective observational study was conducted in a tertiary hospital with six adults with severe CRSwNP, according to EPOS2020 criteria, treated for 52 weeks. All had multiple surgeries (mean 3.3) and high cumulative exposure to systemic corticosteroids. Initially, they presented a high symptom and endoscopic burden (SNOT-22: 72; NPS: 5.2). After 16 and 52 weeks, significant improvements were observed in SNOT-22 (40.3 and 28.8), NPS (4.3 and 2.7), corticosteroid use, and complete eosinophil depletion. VAS scores improved, especially in smell, rhinorrhea, and general condition. No significant adverse events occurred. These preliminary results suggest that benralizumab may be effective in CRSwNP without associated asthma, although larger controlled studies are needed.